“A majority of the patients were categorized as experiencing severe COVID19 at baseline “
That far along in the game, most would have already cleared the virus so an antiviral would have been of little benefit. Looking forward to seeing the remainder of the data(concerning inflammatory markers, secondary infections,etc).
Keep in mind that Merck’s Covid drug failed in hospitalized patients in April and their share price dropped. Now in October they announced that they are repackaging it for outpatient (mild to moderate) and their market cap soared $30B.